60 Degrees C

MarketWatch: 60 Degrees Pharmaceuticals Announces All Patients Cured of Babesiosis After Tafenoquine Treatment in Expanded Use Clinical Trial

WASHINGTON, (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) ("60 Degrees" or the "Company"), a pharmaceutical company focused on developing new medicines for ...

60 Degrees C 2

60 Degrees Pharmaceuticals Announces All Patients Cured of Babesiosis After Tafenoquine Treatment in Expanded Use Clinical Trial

Nasdaq: 60 Degrees Pharmaceuticals Reports Significant Discrepancy in Babesiosis Case Estimates and Plans for New Drug Application in 2026

60 Degrees Pharmaceuticals reports 25,000 U.S. adults claim babesiosis-related medical costs annually, highlighting chronic fatigue as a potential symptom. Highlights significant discrepancy between ...

60 Degrees Pharmaceuticals Reports Significant Discrepancy in Babesiosis Case Estimates and Plans for New Drug Application in 2026

60 Degrees C 6

About 60 Degrees Pharmaceuticals, Inc.60 Degrees Pharmaceuticals, Inc., founded in 2010, specializes in developing and marketing new medicines for the treatment and prevention of vector-borne disease.

Business Insider: 60 Degrees prices 1.5M shares at 71.5c in registered direct offering

60 Degrees C 8

60 Degrees Pharmaceuticals (SXTP) has entered into definitive agreements for the purchase and sale of an aggregate of 1,503,500 shares of its common stock at a purchase price of 71.5c per share in a ...

Business Insider: H.C. Wainwright Remains a Hold on 60 Degrees Pharmaceuticals, Inc. (SXTP)

In a report released today, Edward White from H.C. Wainwright maintained a Hold rating on 60 Degrees Pharmaceuticals, Inc. (SXTP – Research Report). The company’s shares opened today at $1.49.

Seeking Alpha: 60 Degrees Pharmaceuticals Defines Potential Human Babesiosis Market Size for ARAKODA® (tafenoquine): Annual Max TAM, Sales of $245 Million; Cumulative through Patent ...

60 Degrees C 12

60 Degrees Pharmaceuticals Defines Potential Human Babesiosis Market Size for ARAKODA® (tafenoquine): Annual Max TAM, Sales of $245 Million; Cumulative through Patent ...

60 Degrees C 13